Search
Now showing items 21-26 of 26
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
(MDPI, 2021)
The antidiabetic drug gliclazide is partly metabolized by CYP2C19, the main enzyme involved in omeprazole metabolism. The aim of the study was to explore the interaction between omeprazole and gliclazide in relation to ...
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
(John Wiley and Sons Inc, 2022)
The genetic background for interindividual variability of the polymorphic CYP2D6 enzyme activity remains incompletely understood and the role of NFIB genetic polymorphism for this variability was evaluated in this translational ...
Bcs class iv oral drugs and absorption windows: Regional-dependent intestinal permeability of furosemide
(MDPI AG, 2020)
Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet, ~5% of oral drugs on the market belong to this class. While solubility is often ...
Long-Term Effects of Maternal Deprivation on the Volume of Dopaminergic Nuclei and Number of Dopaminergic Neurons in Substantia Nigra and Ventral Tegmental Area in Rats
(Frontiers Media S.A., 2020)
Early life adversities leave long-lasting structural and functional consequences on the brain, which may persist later in life. Dopamine is a neurotransmitter that is extremely important in mood and motor control. The aim ...
Insight into the formation of glimepiride nanocrystals by wet media milling
(MDPI, 2020)
Nanocrystal formation for the dissolution enhancement of glimepiride was attempted
by wet media milling. Di erent stabilizers were tested and the obtained nanosuspensions were
solidified by spray drying in presence of ...
Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis
(Springer Nature Switzerland, 2020)
Drug-induced Mood- and Cognition-related adverse events (MCAEs) are often only detected during the clinical trial phases of drug development, or even after marketing, thus posing a major safety concern and a challenge for ...